Vancouver, British Columbia – March 21, 2016 – Qu Biologics Inc., an immunotherapy company developing Site Specific Immunomodulators (SSIs) for cancer and other inflammatory diseases, announced initial results from the QBECO-01 study, a 68-patient randomized, placebo-controlled clinical study for the treatment of moderate-to-severe Crohn’s disease. Based on the Week 8 and preliminary Week 16 results, […]

Vancouver, British Columbia – November 24, 2015 – Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune function in the targeted organ, announced that it has completed enrollment of its QBECO-01 Crohn’s disease clinical trial, with top-line data expected in late 1Q 2016. Qu Biologics’ QBECO-01 is […]

Vancouver, British Columbia – July 28, 2015 – Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune function in the targeted organ, announced that it has initiated a Phase 2 clinical trial to study QBECO SSI for the treatment of ulcerative colitis. Qu Biologics’ clinical trial in […]

Vancouver, British Columbia – April 24, 2015 – Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body’s normal immune function in the targeted diseased organ, announced today it has opened two new clinical trial sites in Edmonton, Alberta and Toronto, Ontario to enroll participants in its Crohn’s […]

Vancouver, British Columbia – December 4, 2014 – Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune function in the targeted diseased organ, is pleased to welcome gastroenterologist Dr. Remo Panaccione to its Inflammatory Bowel Disease (IBD) advisory team. Qu Biologics’ IBD advisory team provides guidance and […]

Vancouver, British Columbia – October 29, 2014 – Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body’s immune system, announced that an independent Data Safety Monitoring Committee (DSMC) has reviewed the safety data generated from 30 patients (50% enrollment) from Qu Biologics’ current Crohn’s disease clinical trial […]

Crohn’s and Colitis Canada – Western Canada invites you to an evening of inspiration and learning.  Dr. Hal Gunn, immune system expert and founder of Qu Biologics will present “The Immune System and Crohn’s Disease.”  Dr. Hal Gunn will present recent research in Crohn’s disease that has led to the discovery of the company’s investigational […]

Vancouver, British Columbia – April 28, 2014 – Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to “reboot” the body’s immune system, announced that its abstract was selected for a poster presentation at the Digestive Diseases Week conference in Chicago, Illinois on May 4, 2014. Qu Biologics’ poster “Site Specific […]

Vancouver, British Columbia – February 18, 2014 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to “reboot” the body’s innate immune system, announced that its Crohn’s disease clinical trial is now accepting participants from the U.S. “Significant patient interest from the United States in our Crohn’s disease clinical trial […]

Qu Biologics is pleased to welcome microbiology expert Dr. Brian Coombes to Vancouver to give a seminar on his recently published research in Nature Communications demonstrating that infection of mice with a strain of Crohn’s associated adherent-invasive E. coli leads to the development of intestinal inflammation in the mice which closely resembles human Crohn’s disease. […]